Losses
-€41,581 in eight years
Every financial year from 2018 to 2025 closed with a loss. 2022 was the heaviest.
PROMEDITECH
Overview
Lifetime
17 annual accounts with figures on one time axispeak €78,110 (2013)
-€1,600▼ €151
lowest -€52,707 (2011)
-€2,011▼ €206
peak €120,809 (2017)
€79,227▼ 2.5%
€107,757▼ 2.7%
Board1 name since 2008
1 director
Documentsfilings and deeds
29-06-202632 days before the deadline
2025abbreviated format
Loss of €2,011
Key points
from the 2025 annual accountsFilings
17 annual accounts since 2009
The last five annual accounts were filed 27 to 41 days before the end of the period.
At the same address
10 companies
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Resignation: (manager)
Reappointment: (director) · Legal-form conversion: to private limited company · Gazette deed
Incorporation
published on 28-10-2008 · Gazette deed
First establishment
Harenheidestraat 57, Brussels
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| PROMEDITECH Brussels | €186,985 | -€1,600 | 42.4% | - |
| Apotheek Baert S. Bruges | €194,387 | -€7,873 | -21.5% | - |
| FARMACARE Aalst | €226,083 | -€29,654 | 39.6% | - |
| PHARMACIE CHAUSSEE DE GAND Molenbeek-Saint-Jean | €199,651 | -€15,648 | -13.1% | - |
| PHARMACIE BRUNO HENNEGHIEN Tournai | €161,056 | -€17,900 | 0.1% | - |
| PHARMACIE DE LAUZELLE Ottignies-Louvain-la-Neuve | €187,112 | €881 | 99.1% | - |
| PHARMACIE ARNAUD NICOLAS Ixelles | €161,036 | -€10,122 | -58.5% | - |
These companies have the same main activity as PROMEDITECH: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €161,000 and €226,000, founded between 1999 and 2014.
Official details
Source: KBO- Status
- Active since 20-10-2008Normal situation
- Registered office
- 11 active companies are registered at this addressSource: KBO register, as of 12 November 2026.
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Establishment unit
- 2.198.948.9231130 Brussels, since 17-10-2008
- Financial year end
- 31 December
- Peppol
- Reachable
Annual accounts 2025
- -€1,600▼ 10.4%
- €2,011▲ 11.4%
- €79,227▼ 2.5%
- €186,985▼ 2.6%
- Filing
- Filed on 29-06-2026, 32 days before the end of the filing period
Insights on PROMEDITECH
PROMEDITECH files the abbreviated format. That format states no turnover. The gross margin rose from -€17,085 in 2009 to -€1,600 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette.
Financials
Annual accounts 2025
abbreviated format, filed on 29-06-2026, 32 days before the deadline-€1,600
▼ €151
-€2,000
▼ €163
-€2,011
▼ €206
-€46,161
▼ €1,978
42.4%
▲ 0.1 percentage points
0.56
▼ 0.03
Turnover: not included in this filing.
Balance sheet
balance sheet total €186,985 on 31-12-2025What the company ownsHow it is paid for
in euro
in euro
Position in the sector
42.4%
Higher than 56% of 13,234 companies in 2025.
0.56
Higher than 9% of 13,093 companies in 2025.
-1.1%
Higher than 20% of 13,156 companies in 2025.
PROMEDITECH
Middle half of the sector
80% of the sector
Abbreviated accounts in retail trade (NACE 47)
Net result: bottom quarter · Equity: bottom quarter · Balance sheet total: bottom quarter · Working capital: bottom quarter
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet: assets | ||||||||||||||||||
20/58 |
186,985 | 191,967 | 190,682 | 193,005 | 200,303 | 207,423 | 214,381 | 221,329 | 228,159 | 122,243 | 103,526 | 110,070 | 80,166 | 14,226 | 20,493 | 5,005 | 12,356 | |
20 |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 828 | 1,889 | |
21/28 |
127,159 | 127,159 | 127,159 | 127,159 | 127,159 | 127,159 | 127,159 | 127,159 | 127,159 | 28,829 | 973 | 973 | 973 | 973 | 973 | 1,801 | 2,862 | |
28 |
127,159 | 127,159 | 127,159 | 127,159 | 127,159 | 127,159 | 127,159 | 127,159 | 127,159 | 28,829 | 973 | 973 | 973 | 973 | 973 | 973 | 973 | |
29/58 |
59,826 | 64,808 | 63,523 | 65,846 | 73,144 | 80,264 | 87,222 | 94,170 | 101,000 | 93,414 | 102,552 | 109,096 | 79,192 | 13,253 | 19,519 | 3,203 | 9,494 | |
40/41 |
3,189 | 1,420 | 5,842 | 543 | 664 | 248 | 745 | 1,352 | 1,345 | 4,035 | 2,371 | 1,530 | 960 | 12,425 | 11,205 | 2,578 | 1,170 | |
40 |
1,500 | 0 | 4,500 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
41 |
1,689 | 1,420 | 1,342 | 543 | 664 | 248 | 745 | 1,352 | 1,345 | 4,035 | 2,371 | 1,530 | 960 | 12,425 | 11,205 | 2,578 | 1,170 | |
54/58 |
55,099 | 61,824 | 57,618 | 65,290 | 72,480 | 80,015 | 86,477 | 92,817 | 99,654 | 89,379 | 100,167 | 107,533 | 78,185 | 828 | 8,311 | 626 | 6,813 | |
490/1 |
1,538 | 1,564 | 63 | 13 | - | 1 | - | 1 | 1 | 1 | 14 | 34 | 47 | - | 4 | - | 1,511 | |
| Balance sheet: equity and liabilities | ||||||||||||||||||
10/49 |
186,985 | 191,967 | 190,682 | 193,005 | 200,303 | 207,423 | 214,381 | 221,329 | 228,159 | 122,243 | 103,526 | 110,070 | 80,166 | 14,226 | 20,493 | 5,005 | 12,356 | |
10/15 |
79,227 | 81,239 | 83,044 | 85,379 | 92,837 | 100,031 | 107,000 | 113,948 | 120,809 | 14,912 | 21,206 | 27,785 | -2,014 | -67,020 | -60,758 | -8,050 | -708 | |
10/11 |
53,600 | 53,600 | 53,600 | 53,600 | 53,600 | 53,600 | 53,600 | 53,600 | 53,600 | 53,600 | 53,600 | 53,600 | 18,600 | 18,600 | 18,600 | 18,600 | 18,600 | |
100 |
- | - | - | - | - | - | 53,600 | 53,600 | 53,600 | 53,600 | 53,600 | 53,600 | 18,600 | 18,600 | 18,600 | 18,600 | 18,600 | |
13 |
5,360 | 5,360 | 5,360 | 5,360 | 5,360 | 5,360 | 5,360 | 5,360 | 3,360 | - | - | - | - | - | - | - | - | |
130/1 |
5,360 | 5,360 | 5,360 | 5,360 | 5,360 | 5,360 | - | - | - | - | - | - | - | - | - | - | - | |
130 |
- | - | - | - | - | - | 5,360 | 5,360 | 3,360 | - | - | - | - | - | - | - | - | |
1311 |
5,360 | 5,360 | 5,360 | 5,360 | 5,360 | 5,360 | - | - | - | - | - | - | - | - | - | - | - | |
14 |
20,267 | 22,279 | 24,084 | 26,419 | 33,877 | 41,071 | 48,040 | 54,988 | 63,848 | -38,688 | -32,394 | -25,815 | -20,614 | -85,620 | -79,358 | -26,650 | -19,308 | |
17/49 |
107,757 | 110,728 | 107,638 | 107,625 | 107,466 | 107,391 | 107,381 | 107,381 | 107,351 | 107,331 | 82,320 | 82,285 | 82,180 | 81,246 | 81,250 | 13,055 | 13,064 | |
42/48 |
105,986 | 108,990 | 107,638 | 107,625 | 107,466 | 107,121 | 105,931 | 105,931 | 105,931 | 105,931 | 80,931 | 80,931 | 80,931 | 80,000 | 80,000 | 11,815 | 11,824 | |
44 |
27 | 3,031 | 1,707 | 1,695 | 1,535 | 1,191 | - | - | - | - | - | - | - | - | - | 1,815 | 1,824 | |
440/4 |
27 | 3,031 | 1,707 | 1,695 | 1,535 | 1,191 | - | - | - | - | - | - | - | - | - | 1,815 | 1,824 | |
47/48 |
105,960 | 105,960 | 105,931 | 105,931 | 105,931 | 105,931 | 105,931 | 105,931 | 105,931 | 105,931 | 80,931 | 80,931 | 80,931 | 80,000 | 80,000 | 10,000 | 10,000 | |
492/3 |
1,771 | 1,738 | - | - | - | 270 | 1,450 | 1,450 | 1,420 | 1,400 | 1,389 | 1,354 | 1,249 | 1,246 | 1,250 | 1,240 | 1,240 | |
| Income statement | ||||||||||||||||||
76A |
- | - | - | - | - | - | - | - | 110,886 | - | - | - | - | - | - | - | - | |
9900 |
-1,600 | -1,449 | -1,977 | -6,910 | -6,590 | -6,500 | -6,490 | -6,400 | -4,510 | -5,834 | -6,150 | -4,837 | 78,110 | -5,740 | -51,352 | -5,740 | -17,085 | |
630 |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 828 | 1,061 | 1,326 | |
640/8 |
400 | 387 | 384 | 348 | 448 | 348 | 348 | 348 | 348 | 348 | 437 | 437 | 439 | 437 | 437 | 437 | 784 | |
66A |
- | - | - | - | - | - | - | - | - | - | - | - | 12,543 | - | - | - | - | |
9901 |
-2,000 | -1,836 | -2,361 | -7,258 | -7,038 | -6,848 | -6,838 | -6,748 | -4,858 | -6,181 | -6,587 | -5,274 | 77,670 | -6,177 | -52,616 | -7,238 | -19,196 | |
75/76B |
220 | 253 | 225 | 13 | - | 4 | 4 | 4 | 110,891 | 35 | 97 | 195 | 69 | - | 6 | - | 64 | |
75 |
220 | 253 | 225 | 13 | - | 4 | 4 | 4 | 5 | 35 | 97 | 195 | 69 | - | 6 | - | 64 | |
76B |
- | - | - | - | - | - | - | - | 110,886 | - | - | - | - | - | - | - | - | |
65/66B |
231 | 222 | 199 | 214 | 157 | 126 | 115 | 116 | 137 | 147 | 90 | 123 | 190 | 86 | 97 | 105 | 177 | |
65 |
231 | 222 | 199 | 214 | 157 | 126 | 115 | 116 | 137 | 147 | 90 | 123 | 190 | 86 | 97 | 105 | 177 | |
9903 |
-2,011 | -1,805 | -2,335 | -7,458 | -7,194 | -6,969 | -6,948 | -6,860 | 105,896 | -6,294 | -6,579 | -5,201 | 65,006 | -6,262 | -52,707 | -7,342 | -19,308 | |
67/77 |
0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |
9904 |
-2,011 | -1,805 | -2,335 | -7,458 | -7,194 | -6,969 | -6,948 | -6,860 | 105,896 | -6,294 | -6,579 | -5,201 | 65,006 | -6,262 | -52,707 | -7,342 | -19,308 | |
9905 |
-2,011 | -1,805 | -2,335 | -7,458 | -7,194 | -6,969 | -6,948 | -6,860 | 105,896 | -6,294 | -6,579 | -5,201 | 65,006 | -6,262 | -52,707 | -7,342 | -19,308 | |
| Appropriation of the result | ||||||||||||||||||
9906 |
20,267 | 22,279 | 24,084 | 26,419 | 33,877 | 41,071 | 48,040 | 56,988 | 67,209 | -38,688 | -32,394 | -25,815 | -20,614 | -85,620 | -79,358 | -26,650 | -19,308 | |
14P |
22,279 | 24,084 | 26,419 | 33,877 | 41,071 | - | - | - | - | - | - | - | - | - | - | - | - | |
691/2 |
- | - | - | - | - | - | - | 2,000 | 3,360 | - | - | - | - | - | - | - | - | |
6920 |
- | - | - | - | - | - | - | 2,000 | 3,360 | - | - | - | - | - | - | - | - | |
| Document | ||||||||||||||||||
The notes to these accounts have 2 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the accounts filed with the NBB.
Source: Annual accounts 2025 at the NBB, filed on 29-06-2026.
Filings
each dot is a set of accounts, on the day it reached the National Bank| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | abbreviated format | 29-06-2026 | 2026-00219891 | |
| 31-12-2024 | full format | 20-06-2025 | 2025-00160901 | |
| 31-12-2023 | full format | 04-07-2024 | 2024-00212186 | |
| 31-12-2022 | micro format | 20-06-2023 | 2023-00139065 | |
| 31-12-2021 | micro format | 27-06-2022 | 2022-20095328 | |
| 31-12-2020 | micro format | 16-06-2021 | 2021-20100242 | |
| 31-12-2019 | micro format | 05-06-2020 | 2020-14700196 | |
| 31-12-2018 | micro format | 12-06-2019 | 2019-17300286 | |
| 31-12-2017 | full format | 12-06-2018 | 2018-17300124 | |
| 31-12-2016 | full format | 13-06-2017 | 2017-16300495 | |
| 31-12-2015 | full format | 01-07-2016 | 2016-25000539 | |
| 31-12-2014 | full format | 05-07-2015 | 2015-26400530 | |
| 31-12-2013 | full format | 11-06-2014 | 2014-16200234 | |
| 31-12-2012 | full format | 21-06-2013 | 2013-19300353 | |
| 31-12-2011 | full format | 05-07-2012 | 2012-25000130 | |
| 31-12-2010 | full format | 04-07-2011 | 2011-24200145 | |
| 31-12-2009 | full format | 18-06-2010 | 2010-18600311 |
Key figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | -51,789 | -6,177 | -17,869 | ||
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | -51,879 | -6,281 | -17,981 | ||
| - | - | - | - | - | - | - | - | 99,303 | 27,856 | - | - | - | - | 0 | 0 | 973 | ||
| -6,726 | 4,207 | -7,672 | -7,190 | -7,535 | -6,462 | -6,340 | -6,838 | 10,276 | -10,789 | -7,365 | 29,347 | 77,358 | -7,483 | 7,685 | -6,187 | - | ||
| -46,161 | -44,182 | -44,115 | -41,780 | -34,322 | -26,858 | -18,709 | -11,761 | -4,930 | -12,517 | 21,622 | 28,166 | -1,738 | -66,747 | -60,481 | -8,612 | -2,330 | ||
| 42.4% | 42.3% | 43.6% | 44.2% | 46.3% | 48.2% | 49.9% | 51.5% | 52.9% | 12.2% | 20.5% | 25.2% | -2.5% | -471.1% | -296.5% | -160.8% | -5.7% | ||
| 0.56 | 0.59 | 0.59 | 0.61 | 0.68 | 0.75 | 0.82 | 0.89 | 0.95 | 0.88 | 1.27 | 1.35 | 0.98 | 0.17 | 0.24 | 0.27 | 0.80 | ||
| 1.36 | 1.36 | 1.30 | 1.26 | 1.16 | 1.07 | 1.00 | 0.94 | 0.89 | 7.20 | 3.88 | 2.96 | - | - | - | - | - | ||
| -2.5% | -2.2% | -2.8% | -8.7% | -7.7% | -7.0% | -6.5% | -6.0% | 87.7% | -42.2% | -31.0% | -18.7% | - | - | - | - | - | ||
| -1.1% | -0.9% | -1.2% | -3.9% | -3.6% | -3.4% | -3.2% | -3.1% | 46.4% | -5.1% | -6.4% | -4.7% | 81.1% | -44.0% | -257.2% | -146.7% | -156.3% |
EBIT margin: not included in this filing.
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Insights on PROMEDITECH
The operating result for 2025 is a loss of €2,000, larger than the loss of €1,836 in 2024.
Debt's share of the balance-sheet total falls from 57.7% to 57.6%. Equity and debt are lower.
Board & ownership
Board
1 director, last change in 2023Director (not named in the articles)
since 06-06-2023
term without a fixed end
earlier manager, until 13-06-2023
also on the board of 1 other company
listed in the 2025 annual accounts, filed on 29-06-2026
1 other company bankruptMandates through the years
1 name, the dashed line is todayDirector (not named in the articles)
BoardEarliermandate already running before its first mention
Mandates as a list
-
- Director (not named in the articles), from 17-10-2008 to date
- Manager, until 13-06-2023
Control
Capital
- Contribution
- €53,600
- Source
- 2025 annual accounts
Articles of association
deed of 13-06-2023 (in French)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
The directors' other companies
1 current director with another company that went bankrupt, was dissolved or struck off1 other company of this director went bankrupt (2025).
- bankruptcy on 25-04-2025appointed in 2020, still in office
Source: Belgian Official Gazette (bankruptcies, judicial dissolutions, board mandates), FPS Economy (strike-offs) and the KBO register. A bankruptcy, dissolution or strike-off says nothing about the director's part in it.
Network & group
Holdings
own 2025 accountsThis companyPROMEDITECH1 holding, 1 country
2025 accounts
Asia and Oceania 1 Equity Result
- CN CNY 876,403 result CNY 729,127
Source: list of holdings in its own 2025 accounts. The amounts are in that list and come from the holdings' accounts at 31-12-2017, in their own currency.
At the same address
Harenheidestraat 57, 1130 Brussels · 10 other companies| THALY
registered office since 09-06-2000 · founded in 1999 |
total assets €104.9m (2025) 0467.285.127 |
| VANJE
registered office since 17-10-2008 · founded in 2008 |
total assets €29.0m (2025) 0807.224.595 |
| ALLONS VOIR
registered office since 20-09-2018 · founded in 2018 · negative equity (2025) · group THALY |
total assets €6.5m (2025) 0704.841.194 |
| CREALLIANCE
establishment since 22-12-2015 · founded in 2015 |
total assets €2.0m (2023) 0644.764.542 |
| AURORA CONSULTING
registered office since 14-06-2002 · founded in 2002 |
total assets €1.7m (2025) 0477.745.784 |
| F.INITIATIVES
registered office since 09-11-2016 · founded in 2016 · negative equity (2025) |
3.9 FTE (2025) 0665.883.719 |
| DISTRIPHAR
registered office since 27-10-2005 · founded in 2005 |
3 FTE (2025) 0876.852.383 |
| DELMMA
registered office since 24-06-2010 · founded in 2010 |
total assets €370,208 (2025) 0826.937.866 |
| PEPPER CONSULT
establishment since 02-10-2008 · founded in 2008 |
total assets €62,643 (2025) 0806.901.626 |
| TD-CONCEPT
registered office since 08-05-2007 · founded in 2007 |
total assets €13,129 (2025) 0889.269.472 |
Earlier ties
via , no longer at · Director · deed of 07-01-2020 Open bankruptcy · founded in 2015 |
total assets €2.0m (2023) |
Holdings and subsidiaries
1 holdingConnections & network
1 connected companyThe connected companies are in the list below.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Linked via shared directors
via · Director (not named in the articles) · deed of 25-05-2023
Founded in 2008 · total assets €29.0m (2025)
Timeline
Timeline
24 events since 2008Board
Filings
Financial
Establishments
2008201020122014201620182020202220242026
Deadline for the 2026 accounts: 31-07-2027
2026
Annual accounts 2025 filed NBBabbreviated format · 32 days before the deadline
2025
Annual accounts 2024 filed PDFfull format · 41 days before the deadline
2024
Annual accounts 2023 filed PDFfull format · 27 days before the deadline
2023
Annual accounts 2022 filed PDFmicro format · 41 days before the deadline
Resignation: (manager)Reappointment: (director) · Legal-form conversion: to private limited company5 points ▸
- Legal-form conversion, to private limited company
- 536 shares
- Director resignation, (manager)
- Director reappointment, (director (not named in the articles))
- Registered office clause, Bruxelles (1130 Bruxelles) rue Harenheyde, 57
- The deed holds 5 more points.
2022
Annual accounts 2021 filed PDFmicro format · 34 days before the deadline
2021
Annual accounts 2020 filed PDFmicro format · 45 days before the deadline
2020
Annual accounts 2019 filed PDFmicro format · 56 days before the deadline
2019
Annual accounts 2018 filed PDFmicro format · 49 days before the deadline
2018
Annual accounts 2017 filed PDFfull format · 49 days before the deadline
2017
Back to profit net €105,896 The net result is €105,896, after 3 loss-making years.
Equity above €100,000 equity €120,809 ▲710% Equity rises from €14,912 to €120,809.
Annual accounts 2016 filed PDFfull format · 48 days before the deadline
2016
Annual accounts 2015 filed PDFfull format · 30 days before the deadline
2015
Annual accounts 2014 filed PDFfull format · 26 days before the deadline
2014
Annual accounts 2013 filed PDFfull format · 50 days before the deadline
2013
Back to profit net €65,006 The net result is €65,006, after 4 loss-making years.
Annual accounts 2012 filed PDFfull format · 40 days before the deadline
2012
Annual accounts 2011 filed PDFfull format · 26 days before the deadline
2011
Weakest financial year net -€52,707 The net result drops to -€52,707, the lowest from 2009 to 2025. It recovers the following year.
Annual accounts 2010 filed PDFfull format · 27 days before the deadline
2010
Annual accounts 2009 filed PDFfull format · 43 days before the deadline
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Identity
- Enterprise number
- 0807.225.387
- VAT number
- BE 0807.225.387
- Peppol ID
- 0208:0807225387
- Other Peppol ID
- 9925:BE0807225387
- Legal form
- Private limited company
- Status
- Active, normal situation
- Founded
- 20-10-2008
- Financial year
- ends on 31 December
- Peppol
- Reachable via PeppolFollow this company and you will hear the next morning if it leaves the Peppol register.
- Name
- PROMEDITECH in French
- Entity type
- Legal entity
- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimiteddeed of 13-06-2023 (in French)
- Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
- “Région de Bruxelles-Capitale”deed of 13-06-2023 (in French)
Activities
NACEBEL 202547730
Retail sale of pharmaceutical products main activity
Codes under NACEBEL 2008
47730
Retail trade main activity
- PurposeThe purpose describes the activities the company may carry out under its articles.
- “L’achat, la vente de tous produits pharmaceutiques, chimiques, médicinaux, diététiques, hygiène de parfumerie, de beauté, ainsi que de tout…”deed of 13-06-2023 (in French)
14 activities
- L’achat, la vente de tous produits pharmaceutiques, chimiques, médicinaux, diététiques, hygiène de parfumerie, de beauté, ainsi que de tout produit médicaux-chirurgical
- Toute recherche clinique, pharmacologique, thérapeutique et clinique, ainsi que la propagation d’informations médicales et techniques se rapportant aux produits ci-dessus mentionnés
- Plus généralement la recherche, la conception et/ou l’élaboration de technologies relevant du domaine de la santé et/ou de la médication
- L’amélioration et/ou la modification de telles technologies et médications
- La recherche et l’étude de marché dans les domaines pharmaceutiques et parapharmaceutiques et plus généralement ayant trait à la santé
- Pour son propre compte, la constitution et la gestion d'un propre patrimoine mobilier et immobilier, notamment l'acquisition par l'achat ou autrement, la vente, l'échange, la construction, la transformation, l'amélioration, l'équipement, l'aménagement, l'embellissement, l'entretien, la location, la prise en location, le lotissement, la prospection et l'exploitation de biens meubles et immeubles, ainsi que toutes opérations qui, directement ou indirectement sont en relation avec cet objet et qui sont de nature à favoriser l'accroissement et le rapport d'un patrimoine mobilier et immobilier, de même que se porter caution pour la bonne fin d'engagements pris par des tiers.
- La contribution à la constitution de sociétés par voie d'apports, de participations ou d'investissements généralement quelconques;
- L'attribution de prêts et d'ouvertures de crédit aux sociétés et aux particuliers sous quelque forme que ce soit; dans ce cadre, la société peut également se porter caution ou accorder son aval, dans le sens le plus large du terme, réaliser toutes opérations commerciales et financières à l'exception de celles légalement réservées aux banques de dépôt, détenteurs de dépôts à court terme, caisses d'épargne, sociétés hypothécaires et entreprises de capitalisation;
- De dispenser des avis financiers, techniques, commerciaux ou administratifs dans le sens le plus large du terme, à l'exception des conseils de placement d'argent et autres, fournir son assistance et exécuter des services directement ou indirectement sur le plan de l'administration et des finances, de la vente, de la production et de la gestion en général;
- D'exécuter tous mandats d'administrateur, et en général, tous mandats et fonctions se rapportant directement ou indirectement à son objet;
- Le développement, l'achat, la vente, la prise de licences ou l'octroi de licences, de brevets, know-how et d'actifs immobiliers apparentés;
- La prestation de services administratifs et informatiques pur compte de tiers;
- L'achat et la vente, l'importation et l'exportation, le commissionnage, le courtage et la représentation de tous biens généralement quelconques, en bref l'intermédiaire commercial;
- La recherche, le développement, la production ou la commercialisation de nouveaux produits, de nouvelles technologies et leurs applications.
Registered office and establishments
1 establishment| Establishment | Since | Unit number |
|---|---|---|
| Harenheidestraat 57 registered office 1130 Brussels 46460 Wholesale of pharmaceutical and medical goods | 17-10-2008 | 2.198.948.923 |
Buildings and parcels at the address
- Ground area
- 873 m²
- Buildings
- 335 m²
- Volume, LiDAR
- 1,815 m³
- Tallest building
- 7.9 m
Buildings to scale, each on its own parcel
Parcels
| Cadastral parcel | Area | Buildings | Height / floors |
|---|---|---|---|
| 21821B0379/00Y000 | 873 m² | 1 · 335 m² | 7.9 m · 2 |